Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll-like receptor 3 stimulation

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 265-274

  Østvik, Ann E ^a,b   Granlund, Atle V B ^b   Bugge, Marit ^b   Nilsen, Nadra J ^b   Torp, Sverre H ^a,c   Waldum, Helge L ^a,b   Damås, Jan K ^a   Espevik, Terje ^b   Sandvik, Arne K ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Crohn's disease; CXCL10; Poly(I:C); TLR3; Ulcerative colitis

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TOLL LIKE RECEPTOR 3;

ADULT; AGED; ARTICLE; CELL STIMULATION; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; ULCERATIVE COLITIS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; GENE EXPRESSION PROFILING; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLY I-C; RECEPTORS, CXCR3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 3; TRANSCRIPTOME; UP-REGULATION;

EID: 84876420115     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.23034     Document Type: Article

References (32)

1. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565-568.
2. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
3. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150:823-832.
4. Shale M, Ghosh S. Beyond TNF, Th1 and Th2 in inflammatory bowel disease. Gut. 2008;57:1349-1351.
5. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:963-969.
6. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferoninducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177:1809-1814.
7. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
8. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
9. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
10. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987;166:1084-1097.
11. Dwinell MB, Lugering N, Eckmann L, et al. Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology. 2001;120:49-59.
12. Yeruva S, Ramadori G, Raddatz D. NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. Int J Colorectal Dis. 2008;23:305-317.
13. Iijima W, Ohtani H, Nakayama T, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol. 2003; 163:261-268.
14. Uguccioni M, Gionchetti P, Robbiani DF, et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999; 155:331-336.
15. Zahn A, Giese T, Karner M, et al. Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol. 2009;9:13.
16. Manousou P, Kolios G, Drygiannakis I, et al. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte- epithelial cell interaction. J Gastroenterol Hepatol. 2008;23:1823-1833.
17. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1882-1890.
18. Yamamoto J, Adachi Y, Onoue Y, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol. 2000;68:568-574.
19. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985;315:672-676.
20. Papadakis KA, Prehn J, Zhu D, et al. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis. 2004;10:778-788.
21. Yuan YH, ten Hove T, The FO, et al. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7: 281-286.
22. Sauty A, Colvin RA, Wagner L, et al. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol. 2001;167:7084-7093.
23. Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995;95:55-65.
24. Cavassani KA, Ishii M, Wen H, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205: 2609-2621.
25. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010; 10:131-144.
26. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207-215.
27. Yellin M, Peliienko I, Balanescu A, et al. A phase II, randomized, doubleblind, placebo-controlled study evaluating the efficiacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination wtih methorexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:1730-1739.
28. Byrne FR, Winters A, Brankow D, et al. An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation. Autoimmunity. 2009; 42:171-182.
29. Hyun JG, Lee G, Brown JB, et al. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis. 2005;11:799-805.
30. Sasaki S, Yoneyama H, Suzuki K, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol. 2002;32:3197-3205.
31. Singh UP, Singh S, Taub DD, et al. Inhibition of IFN-gammainducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol. 2003; 171:1401-1406.
32. WorldWideWeb7. Avalable at: http://clinicaltrials.gov/ct2/results?term1/ 2MDX-1100. Accessed 21 March 2012.